Search
Search
mobile logo
Search

Publications

Publication Downloads

2024 ASCO® Annual Meeting: Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study

The Lancet 2023: Camrelizumab Plus Rivoceranib Versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): a Randomised, Open-Label, International Phase 3 Study

2024 ASCO® Gastrointestinal Cancers Symposium: Patient-Reported Outcomes (PROs) <65 or ≥65 Years Old From CARES-310 Camrelizumab + Rivoceranib vs Sorafenib as First-Line Treatment for Patients With Unresectable Hepatocellular Carcinoma

2024 ASCO® Gastrointestinal Cancers Symposium: Impact of Baseline Liver Function on Survival Outcomes in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Treated With Camrelizumab + Rivoceranib vs Sorafenib: A Post Hoc Analysis of Study CARES-310

ESMO 2023: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib Plus Trifluridine/Tipiracil in Patients With Previously Treated Metastatic Colorectal Cancer

Clinical Cancer Research 2023: A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Cancer Chemotherapy and Pharmacology 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR2 Inhibitor

2023 ASCO® Annual Meeting: Updated Results From a Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor Rivoceranib for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

2023 ASCO® Annual Meeting: Updated Results From a Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor Rivoceranib for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

2023 ASCO® Annual Meeting: Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study to Evaluate the Bioequivalence of Four Formulations of Oral Rivoceranib Tablets in Healthy Subjects

AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor

AACR 2023: Effect of Rivoceranib on the Pharmacokinetics of Cytochrome P450 Enzyme Substrates: A Phase 1 Trial in Healthy Volunteers

ESMO 2022: Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib Plus Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

2022 ASCO® Annual Meeting: A Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor, Rivoceranib, for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

Gynecologic Oncology: Phase 3 Publication of Efficacy & Safety Results Comparing Paclitaxel Micellar & Cremophor EL-Paclitaxel

2020 ASCO® Annual Meeting: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma

2019 ASCO®-SITC Clinical Immuno-Oncology Symposium: Phase I Study to Evaluate the Safety and Efficacy of Rivoceranib (Apatinib) and Nivolumab in Patients with Unresectable or Metastatic Cancer

AACR 2018: Synergistic Tumor-Suppressive Effect of Apatinib (Rivoceranib), a Selective VEGFR-2 Inhibitor, in Combination With Immunotherapy in a Syngeneic Murine Lung Cancer Model

ACCP 2017: A Phase I Study to Evaluate the Pharmacokinetics of a Single Dose of Apatinib Mesylate (YN968D1) Tablets in Healthy Male Caucasian, Japanese, and Chinese Subjects

2017 ASCO® Annual Meeting: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer: The ANGEL Study

ESMO 2016: A Phase II Study of Apatinib, a Highly Selective Inhibitor of VEGFR-2, in Patients With Metastatic Solid Tumors Without Standard Treatment Options

Stay connected